DeuteRx, LLC, a biopharmaceutical company developing novel small molecule therapeutics, today announced that Chair, President ...

If you’ve been diagnosed with major depressive disorder, seasonal affective depression or any other type of depression, your ...

Zmyra is a non-prescription supplement crafted to support weight loss through appetite suppression, metabolism enhancement, ...

Researchers have discovered in a study published in JAMA Internal Medicine that exposure to typical smoking cessation drugs ...

No increase in risk for major congenital malformations is observed in infants born to mothers receiving smoking cessation therapies, according to a large cohort study.

But semaglutide isn't without side effects. Some users have reported gastrointestinal issues, and a new study suggests that ...

Study authors found a slightly higher risk of hair loss, especially in women, with semaglutide (Ozempic) compared to bupropion-naltrexone. “The risk increase was under 1% for men and just over 2 ...

The European Medicines Agency (EMA) has concluded a review of the weight loss drug naltrexone/bupropion (Mysimba), which was prompted by concerns about potential long-term cardiovascular risks.

Nature Research Intelligence Topics enable transformational understanding and discovery in research by categorising any document into meaningful, accessible topics. Read this blog to understand ...